HK Connect March 2026: Implementation Forecast and Positioning Framework
March Connect implementation is nearing: we forecast expected ADD/DELETE actions and assess how positioning, crowding, and southbound flows may...
535 Views
Pre-IPO Zhejiang Shimai Pharmaceutical - It Might Never Be Possible to Make Money
TCE faces challenges in solid tumors due to cytokine storm, Shimai's reduced R&D investment may hinder clinical trials and commercialization,...
215 Views
HK Biotech IPO 2025: A Statistical Review
A must-read for IPO investors: what drove HK biotech IPO outperformance in 2025 and what still matters heading into 2026.
276 Views
HSCI Index Rebalance Preview and Stock Connect (Mar 2026): Many Changes Following Huge IPO Quarter
There could be 74 changes for the HSCI in March. That could result in 64 changes to the Southbound Stock Connect list and also have implications...
1.5k Views
Hong Kong: IPO SPOTLIGHT - OVERVIEW 2025
Hong Kong is the top global destination for IPOs in 2025, with over HK $280 billion raised so far. Large scale A+H dual listings have surged this...
961 Views